Phathom Pharmaceuticals Income Statement (2018-2026) | PHAT

Income Statement Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.68M1.91M7.32M16.35M29.66M28.52M39.50M49.50M57.58M58.30M
Cost of Revenue (Quarter)
0.17M0.43M1.38M2.36M3.81M3.72M5.04M6.19M7.65M12.00M
Gross Profit (Quarter)
0.52M1.49M5.95M14.00M25.85M24.80M34.47M43.31M49.94M46.30M
Operating items
Research & Development (Quarter)
21.60M16.61M13.55M17.66M18.82M19.02M15.95M11.48M12.76M12.26M13.39M9.43M7.38M8.69M8.58M9.18M9.08M7.03M7.49M7.77M
Selling, General & Administrative (Quarter)
13.72M16.53M19.49M20.25M26.55M23.51M30.70M18.60M18.94M23.40M57.00M62.01M75.87M76.10M76.68M94.47M85.31M51.56M48.37M54.01M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
35.32M33.14M33.04M37.91M45.36M42.53M46.64M30.08M31.70M35.66M70.39M71.44M83.25M84.79M85.27M103.66M94.39M58.59M55.86M61.78M
Operating Income (Quarter)
-35.32M-33.14M-33.04M-37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M-5.93M-15.48M
EBIT (Quarter)
-35.32M-33.14M-33.04M-37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M-5.93M-15.48M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M0.01M0.01M0.11M0.73M1.29M1.46M0.35M2.72M3.35M4.31M3.62M3.71M3.51M2.64M1.79M1.41M1.20M1.74M
Other Non Operating Income (Quarter)
0.01M-2.05M-0.02M-0.01M-0.00M-0.01M-0.09M0.02M0.00M-0.20M-0.01M-0.04M-0.01M-0.01M0.05M-0.02M-0.15M-0.01M-0.01M-0.83M
Non Operating Income (Quarter)
0.01M-3.52M3.96M-0.01M-0.00M-8.56M-0.09M-7.74M0.00M-7.58M24.40M-12.90M-0.01M-14.78M0.05M-15.45M-15.89M-0.01M-61.08M-0.83M
Net income details
EBT (Quarter)
-36.56M-34.61M-35.81M-40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M-21.14M-29.54M
Profit After Tax (Quarter)
-36.55M-36.66M-35.83M-40.66M-50.92M-51.09M-55.05M-37.81M-40.97M-43.24M-79.57M-82.85M-91.45M-85.58M-74.45M-94.32M-75.81M-29.97M-21.15M-30.37M
Income from Continuing Operations (Quarter)
-36.56M-34.61M-35.81M-40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M-21.14M-29.54M
Consolidated Net Income (Quarter)
-36.56M-34.61M-35.81M-40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M-21.14M-29.54M
Income towards Parent Company (Quarter)
-36.56M-34.61M-35.81M-40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M-21.14M-29.54M
Net Income towards Common Stockholders (Quarter)
-36.56M-34.61M-35.81M-40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M-21.14M-29.54M
Additional items
EPS (Basic) (Quarter)
-1.00-0.98-0.95-1.07-1.33-1.32-1.33-0.89-0.84-0.76-1.45-1.42-1.56-1.32-1.00-1.31-1.05-0.41-0.27-0.37
EPS (Weighted Average and Diluted) (Quarter)
-1.00-0.98-0.95-1.07-1.33-1.32-1.33-0.89-0.84-0.76-1.45-1.42-1.56-1.32-1.00-1.31-1.05-0.41-0.27-0.37
Shares Outstanding (Weighted Average) (Quarter)
36.64M37.30M37.00M38.04M38.16M38.38M39.12M42.35M48.50M49.27M51.29M58.37M58.46M64.63M63.18M71.97M72.22M73.40M72.92M82.05M
Shares Outstanding (Diluted Average) (Quarter)
36.47M37.30M37.00M38.04M38.27M38.82M39.12M42.35M45.44M56.78M51.29M58.37M58.46M60.54M63.18M71.97M72.22M72.62M72.92M82.05M
EBITDA (Quarter)
-35.32M-33.14M-33.04M-37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M-5.93M-15.48M
Interest Expenses (Quarter)
1.26M1.49M2.77M2.76M5.67M9.28M9.60M9.22M9.62M10.11M13.03M17.17M17.76M18.48M18.59M18.07M17.52M16.11M16.42M15.80M